P2.16-03 RYZ101 + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor Expressing Extensive-Stage Small-Cell Lung Cancer

RYZ101 (225Ac-DOTATATE) is a first-in-class, highly potent alpha-emitting radiopharmaceutical therapy in development for somatostatin receptor expressing (SSTR2+) solid tumors. Alpha-particles (as emitted by 225Ac) have a shorter path length (40-100 μm) and higher linear energy transfer (80-100 keV/μm) than beta-particles, potentially allowing for higher cancer cell kill rates and less damage to healthy tissues. We describe the design of a single-arm, open-label, phase 1b dose-escalation and dose-expansion trial of RYZ101 in combination with standard of care (SoC) therapy in patients with SSTR+ extensive-stage small-cell lung cancer (ES-SCLC; NCT05595460).